Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure

Although the haemodynamic effects of angiotensin receptor‐neprilysin inhibitor (ARNI) on patients with heart failure have been demonstrated, the effect on glucose metabolism has not been fully elucidated. We retrospectively investigated the effect of ARNI on abnormal glucose metabolism in patients with stable chronic heart failure using an additional structural equation model (SEM) analysis.

[1]  T. Tachibana,et al.  Exogenous ANP Treatment Ameliorates Myocardial Insulin Resistance and Protects against Ischemia–Reperfusion Injury in Diet-Induced Obesity , 2022, International journal of molecular sciences.

[2]  Sanjiv J. Shah,et al.  Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials , 2022, Cardiovascular Diabetology.

[3]  M. Kawai,et al.  Heart Failure Treatments Such As Angiotensin Receptor/Neprilysin Inhibitor Improve Heart Failure Status and Glucose Metabolism , 2022, Cureus.

[4]  M. Yoshimura,et al.  URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice , 2021, Molecular metabolism.

[5]  M. Connelly,et al.  Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study , 2021, Cardiovascular Diabetology.

[6]  M. Yoshimura,et al.  Treatment with atrial natriuretic peptide induces adipose tissue browning and exerts thermogenic actions in vivo , 2021, Scientific Reports.

[7]  J. Bauersachs.  Heart failure drug treatment: the fantastic four , 2021, European heart journal.

[8]  Akshay S. Desai,et al.  Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF , 2020, European journal of heart failure.

[9]  D. Rubello,et al.  The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  S. Solomon,et al.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. , 2019, JAMA.

[11]  J. Vercammen,et al.  Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction , 2019, Clinical Research in Cardiology.

[12]  Akshay S. Desai,et al.  Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF , 2017, European journal of heart failure.

[13]  N. Xu,et al.  Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. , 2017, American journal of physiology. Renal physiology.

[14]  Y. Moriwaki,et al.  Nonpharmacological Management of Gout and Hyperuricemia: Hints for Better Lifestyle , 2017, American journal of lifestyle medicine.

[15]  G. Sesti,et al.  Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-&kgr;B Signaling Pathway in HepG2 Cells , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[17]  M. Kawai,et al.  The impact of an inverse correlation between plasma B-type natriuretic peptide levels and insulin resistance on the diabetic condition in patients with heart failure. , 2016, Metabolism: clinical and experimental.

[18]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[19]  C. Baylis,et al.  Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome , 2011, Diabetes.

[20]  David L. Brown,et al.  Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). , 2007, The American journal of cardiology.

[21]  David Bell,et al.  Functional class in patients with heart failure is associated with the development of diabetes. , 2003, The American journal of medicine.

[22]  K. Shimamoto,et al.  Blockade of the Renin-Angiotensin System Increases Adiponectin Concentrations in Patients With Essential Hypertension , 2003, Hypertension.

[23]  K. Shimamoto,et al.  The contribution of skeletal muscle tumor necrosis factor‐α to insulin resistance and hypertension in fructose‐fed rats , 2000, Journal of hypertension.

[24]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[25]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[26]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[27]  富樫 信彦,et al.  The contribution of skeletal muscle tumor necrosis factor-α to insulin resistance and hypertension in fructose-fed rats , 2001 .